KMTS — Kestra Medical Technologies Income Statement
0.000.00%
Last trade - 00:00- $1.20bn
- $1.18bn
- $27.81m
Annual income statement for Kestra Medical Technologies, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2020 April 30th | 2021 April 30th | 2023 April 30th | 2024 April 30th | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 7.63 | 27.8 |
| Cost of Revenue | ||||
| Gross Profit | — | — | -10.7 | 0.362 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 29.3 | 32.7 | 88.1 | 114 |
| Operating Profit | -29.3 | -32.7 | -80.4 | -86.1 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -29.3 | -33.9 | -84.2 | -94.1 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -29.5 | -34.1 | -84.2 | -94.1 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -29.5 | -34.1 | -84.2 | -94.1 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -29.5 | -34.1 | -86.7 | -101 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.595 | -0.688 | -1.75 | -2.02 |